Obesity may mediate early stages of subclinical atherosclerotic disease in patients with type 2 diabetes, whereas hyperglycemic and insulin resistance may contribute to the progression of later stages.
Read More »Issue159 Item 13 Fasting And Post-Challenge Hyperglycemia Indicates Distinct Pat
Two measurements may represent distinct phenotypic pathways in the evolution of type 2 diabetes, new research suggests.
Read More »Issue 159 Item 14 New Target for Antidiabetic Agents Identified
New Target for Antidiabetic Agents Identified U.S. researchers identify a protein that could serve as a new target for drugs designed to treat type II diabetes. The protein, known as TRB3, is actually a homolog of a protein found in the fruit fly Drosophila tribbles, senior author Dr. Marc Montminy, …
Read More »Issue 159 Item 15 Walking Less Then 20 Minutes A Day! Reduces Risk of Heart Dise
Walking Less Then 20 Minutes A Day! Reduces Risk of Heart Disease 61% Moderation is the key to sustaining exercise. Two studies show that exercise for less than 20 minutes a day and in moderation can reduce the risk of heart disease by 61%The first study shows that physical activity …
Read More »BMI Calculator for use on Palm OS and PocketPC 2003 Devices
Download your free program for your handheld device. Compliments of the educational mission of the Obesity Education Initiative (OEI) of the NIH National Heart, Lung, and Blood Institute. Click Here for More
Read More »FDA Approves First Insulin Drug Vetsulin ® for Diabetic Dogs
For the first time, mans best friend will now have his own non-human insulin. The FDA has approved a porcine insulin zinc suspension product as the first drug for treating diabetic dogs. Prior to the development of this product, the only treatment veterinarians could use on diabetic dogs was human …
Read More »Children’s Medical Id Bracelet
Many children don’t wear medical alert identification because it draws attention to their condition. The Beadin’ Beagle now offers a fashionable alternative to the standard medical identification bracelet! For more styles Click Here
Read More »LAF237 is the lead DPP-IV inhibitor compound from Novartis.
Preliminary results of 12 week Phase 2 studies show LAF237 was well tolerated and demonstrated surprising glucose-lowering potency both as monotherapy, and in combination with metformin. Novartis is proceeding to Phase 3 Clinical Trials with this compound. See this weeks Item #2. To get slides on how LAF237 works
Read More »Flat-D
Last year when I first heard about the Flat-D pad, from Frank Morosky of FLAT-D innovations, I thought it was a joke. But after seeing some of the comments of users and doing some more research into why diabetes patients get gas, I now know why Frank called me. To …
Read More »The DigiScope
The DigiScope
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.